Work

Abstract PR015: Novel digital PCR ctDNA monitoring assay evaluating exceptional responders to combination immune-oncology (IO) therapy

Year: 2024

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.liqbiop24-pr015

Author: Daniel Stetson

Institution: AstraZeneca (United States)

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404318491

Cites:

Cited by:

Related to: 10